Methods and vectors for generating antibodies in avian species and uses therefor

• US 6,951,742 B1
• Filed: 05/16/2000
• Issued: 10/04/2005
• Est. Priority Date: 11/16/1998
• Status: Expired due to Fees

• Current Assignee: Genway Biotech, Inc. (Aviva Systems Biology Corp.)
• Original Assignee: Genway Biotech, Inc. (Aviva Systems Biology Corp.)
• Inventors: Duan, Lingxun
• Primary Examiner(s): Moran, Marjorie
• Assistant Examiner(s): Clow, Lori A.
• Application Number:
  US09/573,442
• Time in Patent Office: 1,967 Days
• Field of Search: 204/450, 435/320.1, 435/69.1, 435/69.3, 435/91.4, 435/6, 435/7.1, 536/231, 536/23.5, 530/387.1, 530/389.1, 702/19
• US Class Current: 435/69.3
• CPC Class Codes: A61K 2039/53 DNA (RNA) vaccination
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C07K 14/70596 Molecules with a "CD"-designation not provided for elsewhere
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002
• CPC Class Codes: C07K 16/02 from eggs
• CPC Class Codes: C12N 2730/10122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 9/1252 DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
• CPC Class Codes: C12Q 1/6809 Methods for determination or identification of nucleic acids involving differential detection
• CPC Class Codes: Y02A 90/10 Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

The present invention relates to processes for producing polyclonal and monoclonal antibodies to an antigen in an avian species, preferably in a chicken, using polynucleotide vaccination. The present invention also relates to processes for determining the proteomics profile of a set of pre-selected DNA sequences isolated from a bio-sample, preferably the proteomics profile of a human cDNA library. The present invention additionally relates to processes for identifying physiologically distinguishable markers associated with a physiologically abnormal bio-sample. The present invention further relates to antibody arrays, integrated databases for identification of genes and proteins, multi-functional gene expression vectors, and methods of producing and using such antibody arrays, integrated databases and multi-functional gene expression vectors.

Claims

1. A process for assessing a proteomics profile of a set of pre-selected DNA sequences isolated from a bio-sample, which comprises:

1) cloning each of said DNA sequences into a dual-expression vector that is capable of expressing said DNA sequences in chicken cells, non-chicken cells or in vitro expression systems;

2) delivering said DNA sequence in said dual-expression vector formed in step

     1), or protein encoded by said DNA sequence, or a mixture thereof, to a chicken in an amount sufficient to induce detectable production of antibodies to an antigen encoded by said DNA sequence, and recovering said antibodies from said chicken;

3) delivering said DNA sequence, which is delivered to said chicken in step

     2), to said non-chicken cells, and recovering proteins or peptides encoded by said DNA sequence from said non-chicken cells, or expressing and recovering proteins or peptides encoded by said DNA sequence in said in vitro expression systems;

4) conducting immunoreactions between said antibodies recovered in step

     2) with said proteins or peptides recovered from step

     3) to characterize the immunospecificity of said antibodies; and

5) conducting immunoreactions between said antibodies recovered in step

     2) with said bio-samples to determine the proteomics profile of said set of pre-selected DNA sequences.

2. The process of claim 1, wherein the set of pre-selected DNA sequences is a cDNA library.

3. The process of claim 2, wherein the cDNA library encodes secreted proteins or peptides in the bio-sample.

4. The process of claim 1, wherein the bio-sample is of human origin.

5. The process of claim 1, wherein the dual-expression vector is a pS&

DV vector comprising a ColE1 replication origin, a CMV promoter, a T7/Lac operon, a RBS/Kozak region, a polilinker region, a T7 termination region and an Amp gene.

6. The process of claim 1, wherein the non-chicken cells are animal, plant, or fungus cells.

7. The process of claim 1, wherein the non-chicken cells are bacterium cells.

8. The process of claim 1, wherein the DNA sequence is delivered to the chicken.

9. The process of claim 8, wherein the DNA sequence is delivered directly to a tissue of the chicken.

10. The process of claim 9, wherein the tissue is selected from the group consisting of muscle, skin and mucous membrane.

11. The process of claim 9, wherein the DNA sequence is delivered by injection, by gene gun technology or by lipid mediated delivery technology.

12. The process of claim 8, wherein the DNA sequence is delivered to a cell of the chicken and said cell containing the DNA sequence is delivered to a suitable tissue of the chicken.

13. The process of claim 12, wherein the cell is selected from the group consisting of a blood cell and a spleen B cell.

14. The process of claim 12, wherein the DNA sequence is delivered to the cell by a method selected from the group consisting of Ca₃(PO₄)₂-DNA transfection, DEAE dextran-DNA transfection, electroporation, transfection using (1:

1 (w/w) liposome formulation of the cationic lipid N-[1-(2,3-dioleyloxy)propyl]-n,n,n-trimethylammonium chloride (DOTMA), and dioleoyl phosphotidylethanolamine (DOPE) in membrane filtered water, gene gun technology and viral gene delivery system.

15. The process of claim 8, wherein the DNA sequence encoding the antigen is contained and delivered in a viral vector derived from an adenovirus.

16. The process of claim 8, wherein the DNA sequence encoding the antigen is contained and delivered in a viral vector.

17. The process of claim 1, wherein the protein encoded by the DNA sequence is delivered to the chicken.

18. The process of claim 1, wherein the antibodies are recovered from egg yolk of the chicken.

19. The process of claim 18, wherein the antibodies are purified from the egg yolk by ammonium sulfate precipitation, by polyethylene glycol 6000 precipitation or by caprylic acid precipitation.

20. The process of claim 1, wherein the antibodies are recovered from antibody-producing B cells of the chicken.

21. The process of claim 1, wherein the non-chicken cells are E. coli cells.

22. The process of claim 1, wherein the immunoreactions are assayed by immunoblotting, immunoprecipitation or in situ immunostaining.

23. The process of claim 1, wherein in step 5) the immunoreactions are conducted to determine the existence, quantity, subcellular location or tissue expression specificity of proteins or peptides encoded by the set of pre-selected DNA sequences in evaluating the proteomics profile of the set of pre-selected DNA sequences in the bio-sample.

24. The process of claim 1, wherein the pre-selected DNA sequences are isolated from a physiologically normal bio-sample.

25. The process of claim 1, wherein the pre-selected DNA sequences are isolated from a physiologically abnormal bio-sample.

26. The process of claim 1, wherein the DNA sequence further comprises a sequence that directs secretion of the encoded antigen in the chicken.

27. The process of claim 26, wherein the secretion-directing sequence is a leader sequence.

28. The process of claim 27, wherein the leader sequence is an endogenous leader sequence of the chicken.

29. The process of claim 27, wherein the leader sequence is selected from the group consisting the leader sequence of chicken IgY, chicken Secreted Protein, Acidic, Rich in Cysteine (SPARC), chicken serum albumin and chicken tissue-type plasminogen activator (tPA).

30. The process of claim 27, wherein the leader sequence is selected from the group consisting of the leader sequence of IL-1, CD4 and MHC.

31. A process for identifying physiologically distinguishable markers associated with a physiologically abnormal bio-sample, which comprises:

1) assessing a proteomics profile of said physiologically abnormal bio-sample through the process of claim 1;

2) assessing a proteomics profile of a comparable physiologically normal bio-sample through the process of claim 1; and

3) comparing the proteomics profile obtained in step

     1) with the proteomics profile obtained in step

     2) to identify physiologically distinguishable markers associated with a physiologically abnormal bio-sample.

32. A method for identifying a substance that modulates a proteomics profile of a bio-sample, which method comprises:

1) assessing a proteomics profile of a bio-sample through the process of claim 1 in the presence of a test substance;

2) assessing a proteomics profile of said bio-sample through the process of claim 1 in the absence said test substance; and

3) comparing the proteomics profile obtained in step

     1) with the proteomics profile obtained in step

     2),

whereby the existence of a difference between the proteomics profile obtained in step

     1) and the proteomics profile obtained in step

     2) identifies the test substance as a modulator of said proteomics profile of said bio-sample.

33. The process of claim 1, wherein a mixture of the DNA sequence and the protein encoded by the DNA sequence is delivered to the chicken.

34. The process of claim 1, wherein the immunoreactions are assayed by an antibody array or an tissue array.